Skip to main content

Accessibility Tools
Oncology patient

Case Study

A Smart Hybrid Comparator Sourcing Model for Global Oncology Trial Success
Asia Female Pharmacist Using Digital Tablet while Taking Inventory

Challenge

In the context of a global Phase Ib oncology study, the sponsor needed to source, label and distribute Keytruda and Erbitux across a wide range of countries, some of which were subject to extremely tight start-up timelines.

The high value of these comparators made waste reduction a priority, while limited availability of the required products along with necessary documentation posed sourcing challenges.

The sponsor also aimed to minimize cross-border shipments to reduce both costs and environmental impact.

Achieving these goals required a carefully tailored strategy that balanced local sourcing – where possible – with centralized supply and distribution for regions where local access was constrained.

The complexity of this setup called for a highly flexible and responsive partner capable of designing a dynamic sourcing model and navigating varied regional regulations.

The Myonex Solution

To meet these challenges, Myonex developed a hybrid supply strategy based on a thorough analysis of the study protocol, local drug availability, pricing conditions, and regional lead times.

In countries where local sourcing was feasible – such as the United States, Australia, the United Kingdom, Spain, and Germany – Myonex leveraged its CTRx™ partner network of pharmacies and wholesalers. This approach enabled on-demand local supply without need for relabeling nor import/export, which cumulatively accelerated timelines and saved costs significantly.

In regions where local sourcing was not viable, including Latin America, APAC, Turkey, Moldova, Georgia, Switzerland, and other EU countries, Myonex implemented a centralized sourcing and distribution model via Myonex Berlin (DE) including relabeling operations.

This hybrid setup allowed for rapid study initiation in priority countries within 30 days using CTRx™ solution, while global waste was minimized thanks to the unique CTRx™ approach, and continuous forecasting and demand planning for central supply.

Throughout the process, Myonex ensured clear and streamlined communication by providing the sponsor with a single point of contact.
 

Results

  • Efficient Global Coverage: Successfully supported sourcing and then distribution in diverse regions.
  • Accelerated Start-up: Countries leveraging the CTRx model were study-ready in 30 days.
  • Minimized Waste: Just-in-time supply through local channels and adaptive forecasting for central supply ensured efficient use of comparators.
  • Cost-effectiveness: The overall competitive cost resulted from reduced waste, optimized pricing across countries, and the elimination – through local sourcing – of the need and associated costs of relabeling.
  • Operational Simplicity: This streamlined process managed entirely by Myonex ensured seamless coordination across all sourcing models.
Female hospice patient smiles at her visiting nurse

Conclusion

This project showcased Myonex’s ability to deliver a flexible and cost-effective supply strategy for a complex global oncology trial. By intelligently combining local and central sourcing, Myonex enables the sponsor to launch quickly, reduce drug waste, optimize costs, and maintain regulatory compliance across multiple regions.

With Myonex, the sponsor gained a reliable partner capable of adapting to local constraints while delivering global consistency – contributing to the successful execution of a strategic Phase Ib study.